Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & Dosage

Iressa

[gefitinib tablets]

Patients often present with the acute onset of dyspnea, sometimes associated with cough or low- grade fever, often becoming severe within a short time and requiring hospitalization. ILD has occurred in patients who have received prior radiation therapy (31% of reported cases), prior chemotherapy (57% of reported patients), and no previous therapy (12% of reported cases). Patients with concurrent idiopathic pulmonary fibrosis whose condition worsens while receiving IRESSA have been observed to have an increased mortality compared to those without concurrent idiopathic pulmonary fibrosis.

In the event of acute onset or worsening of pulmonary symptoms (dyspnea, cough, fever), IRESSA therapy should be interrupted and a prompt investigation of these symptoms should occur. If interstitial lung disease is confirmed, IRESSA should be discontinued and the patient treated appropriately (see WARNINGS-Pulmonary Toxicity, PRECAUTIONS-Information for Patients and DOSAGE AND ADMINIS-TRATION- Dosage Adjustment sections). In patients receiving IRESSA therapy, there were reports of eye pain and corneal erosion/ ulcer, sometimes in association with aberrant eyelash growth (see PRECAU-TIONS- Information for Patients section).

Text Continues Below



There were also rare reports of pancre-atitis and very rare reports of corneal membrane sloughing, ocular ischemia/ hemorrhage, toxic epidermal necrolysis, erythema multiforme, and allergic reactions, including angioedema and urticaria. International Normalized Ratio (INR) elevations and/ or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy. Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR (see CLINICAL PHARMACOLOGY-Drug-Drug Interactions and PRECAUTIONS-Drug Interactions sections). Data from non-clinical (in vitro and in vivo) studies indicate that gefitinib has the potential to inhibit the cardiac action potential repolarization process (eg, QT interval). The clinical relevance of these findings is unknown.

Page:  << Prev | 1 | 2 | 3 | 4 | Next >>







New Features

New ADHD Site!


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.